To evaluate the efficacy of lithium in the treatment of acute mania.
response between lithium and control treatment was used as the weight. The same approach was used for both the BPRS and the CGI. Efficacy was also estimated in the rate ratio. In the pooling of the rate ratios, the individual log rate ratio weighted by the inverse of the variance was used. The number needed to treat was calculated from the pooled rate difference.
How were differences between studies investigated?
A random-effects model was used where the results were considered heterogeneous on the basis of the Q-statistic for heterogeneity (0.05 level of significance).
Results of the review
Twenty-two trials were included in a detailed analysis. A total of 658 patients from 12 trials were pooled.
The response rate ratio for lithium against placebo was 1.95 (95% CI: 1.17,3.23). The mean number needed to treat was five (95% CI: 3, 20). Patients were twice as likely to obtain remission with lithium than with chlorpromazine (rate ratio = 1.96, 95% CI: 1.02, 3.77). The mean number needed to treat was four (95% CI: 3,9). Neither carbamazepine nor valproate was more effective than lithium. The response rate ratios were 1.01 (95% CI: 0.54, 1.88) for lithium compared to carbamazepine and 1.22 (95% CI: 0.91, 1.64) for lithium against valproate. Haloperidol was no better than lithium on the basis of improvement based on assessment of global severity. The differences in effects between lithium and risperidone were -2.79 (95% CI: -4.22,-1.36) in favour of risperidone with respect to symptom severity improvement and -0.76 (95% CI: -1.11,-0.41) on the basis of reduction in global severity of disease. Symptom and global severity was as well controlled with lithium as with verapamil. Lithium caused more side-effects than placebo and verapamil, but no more than carbamazepine or valproate.
